Unilabs has partnered with C2N Diagnostics, a developer of Alzheimer's diagnostic solutions, to expand access to C2N's Precivity blood tests.
The multi-year partnership will make C2N's Precivity portfolio of blood tests available exclusively in Europe, including Norway, Switzerland, and the UK, as well as in Peru, Saudi Arabia, and the UAE. The agreement will facilitate a technology transfer of C2N's Alzheimer's blood biomarkers to deliver a Unilabs testing network across Europe.
C2N's Precivity blood tests aid in detecting amyloid plaques and tau tangles in the brain, which are hallmarks of Alzheimer's disease. The tests are intended for patients 55 years and older with signs of mild cognitive impairment or dementia and are only available for order by qualified healthcare providers.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.